Modelling the genital herpes epidemic

Herpes

Volumn 11, Issue SUPPL. 3, 2004, Pages

  Blower, Sally ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Antiviral therapy; Drug resistance; Epidemic; Genital herpes; HSV; Mathematical modelling; Transmission

Indexed keywords

ANTIVIRUS AGENT; HERPES SIMPLEX VACCINE;

CONFERENCE PAPER; EPIDEMIC; GENITAL HERPES; HERPES SIMPLEX VIRUS 2; HUMAN; IMMUNOCOMPETENCE; MATHEMATICAL MODEL; PREVALENCE; PRIORITY JOURNAL; RECURRENT INFECTION; SAFE SEX; VIRUS REACTIVATION; VIRUS SHEDDING; VIRUS TRANSMISSION;

HERPES GENITALIS; HUMANS; MODELS, THEORETICAL;

HERPES; HUMAN HERPESVIRUS 2;

EID: 4344617294     PISSN: 09697667     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (16)

1. Blower SM, Porco TC, Darby G. Predicting and preventing the emergence of antiviral drug resistance in HSV-2. Nat Med 1998;4:673-678.
2. Gershengorn HB, Blower SM. Impact of antivirals and emergence of drug resistance: HSV-2 epidemic control. AIDS Patient Care STDs 2000;14: 133-142.
3. Gershengorn HB, Darby G, Blower SM. Predicting the emergence of drug-resistant HSV-2: new predictions BMC Infect Dis 2003;3:1.
4. Blower SM, Dowlatabadi H. Sensitivity and uncertainty analysis of complex models of disease transmission: an HIV model as an example. Int Stat Rev 1994;2:229-243.
5. Marchant J, Roe A. Genital herpes: recognizing and addressing patients' needs. Herpes 1997;4:36-41.
6. Whitley RJ, Gnann JW, Jr. Acyclovir: a decade later. N Engl J Med 1992;327: 782-789.
7. Field HJ, Wildy P. The pathogenicity of thymidine kinase-deficient mutants of herpes simplex virus in mice. J Hyg (Lond) 1978;81:267-277.
8. Blyth WA, Harbour DA, Hill TJ. Effect of acyclovir on recurrence of herpes simplex skin lesions in mice. J Gen Virol 1980;48:417-419.
9. Blower SM, Wald A, Gershengorn HB, Wang F, Corey L. Targeting virological core groups: a new paradigm for controlling HSV-2 epidemics. J Infect Dis 2004 (in press).
10. White PJ, Garnett GP. Use of antiviral treatment and prophylaxis is unlikely to have a major impact on the prevalence of herpes simplex virus type 2. Sex Transm Infect 1999;75:49-54.
11. Corey L, Wald A, Patel R, Sacks SL, Warren T, Douglas JM et al. Once-daily valacyclovir to reduce the transmission of genital herpes. N Engl J Med 2004;350:11-20.
12. Mindel A. Is it meaningful to treat patients with recurrent herpetic infections? Scand J Infect Dis Suppl 1991;80: 27-32.
13. Schinazi RB. Strategies to control the genital herpes epidemic. Math Biosci 1999;159:113-121.
14. Newton EA, Kuder JM. A model of the transmission and control of genital herpes. Sex Transm Dis 2000;27:363-370.
15. Fleming DT, McQuillan GM, Johnson RE, Nahmias AJ, Aral SO, Lee FK et al. Herpes simplex virus type 2 in the United States, 1976 to 1994. N Engl J Med 1997;337: 1105-1111.
16. Blower SM, Li M. Calculating the contribution of HSV-2 epidemics to increasing HIV incidence rates: treatment implications. Clin Infect Dis 2004 (in press).